NEW YORK, Nov. 2, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of Metagenomi, Inc. (NASDAQ: MGX) pursuant and/or traceable to the Company's initial public offering conducted between February 9 and 13, 2024 (the "IPO"), of the important November 25, 2024 lead plaintiff deadline.So what: If you purchased Metagenomi stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.What to do ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Metagenomi, Inc. stock during its IPO of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Company Overview - Metagenomi, Inc. is described as a "genetic medicines company" that had a collaboration with Moderna, a leading Covid-19 vaccine company [4] - The company completed its IPO on February 13, 2024, selling 6.25 million shares at a price of $15 per share [4] Group 2: Legal Proceedings - A class action lawsuit has been filed against Metagenomi following the termination of its collaboration agreement with Moderna on May 1, 2024, which allegedly caused investor damages [4] - Investors who purchased Metagenomi stock during the IPO may be entitled to compensation through a contingency fee arrangement [1][2] Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest ever against a Chinese company [3] - The firm has been consistently ranked among the top firms for securities class action settlements since 2013, recovering hundreds of millions for investors [3]

Core Insights - A lawsuit has been filed against Metagenomi, Inc. (NASDAQ: MGX) for alleged violations of securities laws, with a deadline for affected investors to act by November 25, 2024 [1][4]. Company Overview - Metagenomi, Inc. completed its initial public offering (IPO) on February 13, 2024, selling approximately 6.25 million shares at $15 per share [3]. - Following the termination of a collaboration agreement with Moderna on May 1, 2024, shares of Metagenomi, Inc. have declined by over 85% [3]. Legal Proceedings - The lawsuit claims that the defendants made materially false and misleading statements regarding the company's business and prospects, seeking to compensate investors who purchased shares during the IPO and suffered losses [4]. - Investors who incurred losses exceeding $100,000 are encouraged to contact the Shareholders Foundation for assistance [2].

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Metagenomi, Inc. (NASDAQ: MGX). Shareholders who purchased shares of MGX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/metagenomi-loss-submission-form/?id=109668&from=3 CLASS PERIOD: This lawsuit is on ...

NEW YORK, Oct. 28, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Metagenomi, Inc. (NASDAQ: MGX). Shareholders who purchased shares of MGX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/metagenomi-loss-submission-form/?id=109394&from=4 CLASS PERIOD: This lawsuit is on beha ...

Core Insights - Metagenomi's Adenine Base Editors (ABEs) demonstrate over 95% genome targetability and achieve over 95% protein knockdown in primary T-cells, indicating high efficiency and specificity in gene editing applications [1][2][3] Group 1: Targetability - The ABE platform is targetable to over 95% of the human genome's base pairs, providing a significantly wider range of sites compared to first-generation SpCas9 base editors, which enhances flexibility in addressing complex gene targets [2][3] Group 2: Efficiency - The ABE platform achieved over 95% reproducible and durable triplex protein knockdown in primary T-cells, confirming its efficiency for multiplex gene editing [3] - The platform is compatible with various non-viral methods for site-specific template integration, enabling a comprehensive editing solution for next-generation cell therapies [3] Group 3: Specificity - The ABE demonstrated highly specific on-target deamination with minimal to no indel formation, confirming no detectable translocations and no significant genomic composition differences compared to unedited cells, which minimizes the risk of unintended genetic alterations [3] Group 4: Tolerability - ABE triplex protein knockdowns exhibited excellent tolerability in cells, with no adverse effects on cell viability, expansion, or changes in stress-related gene expression observed post-editing, which is critical for maintaining cell health in therapeutic applications [4] Group 5: Company Overview - Metagenomi is a precision genetic medicines company focused on developing curative therapeutics using its proprietary metagenomics-derived toolbox, which includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems [5]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Metagenomi, Inc. regarding a class action lawsuit related to the company's initial public offering and subsequent termination of its collaboration with Moderna, which has impacted the stock price significantly [1][3]. Summary by Sections Class Action Details - The lawsuit is on behalf of shareholders who purchased Metagenomi stock during the class period from February 9 to 13, 2024, coinciding with the company's IPO [2]. - Shareholders are encouraged to register for participation in the class action, with a deadline set for November 25, 2024 [4]. Allegations and Impact - Metagenomi presented itself as a "genetic medicines company" with a strategic partnership with Moderna, which was a key aspect of its business model [3]. - The company completed its IPO on February 13, 2024, selling 6.25 million shares at $15 each, but announced the termination of its collaboration with Moderna on May 1, 2024 [3]. - Following the announcement, Metagenomi's stock price fell from $7.04 on May 1, 2024, to $6.17 on May 2, 2024, indicating a significant market reaction to the news [3]. Next Steps for Shareholders - Shareholders who register will receive updates through a portfolio monitoring software regarding the case's progress [4]. - There is no cost or obligation for shareholders to participate in the class action [4]. Law Firm Background - The Gross Law Firm is recognized for its commitment to protecting investors' rights and addressing issues of deceit and fraud in business practices [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Metagenomi, Inc. due to alleged violations of federal securities laws related to misleading statements about its collaboration with Moderna, which has led to significant investor losses [1][2]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses exceeding $50,000 in Metagenomi between February 9, 2024, and September 26, 2024, to discuss their legal options [1]. - A federal securities class action has been filed against Metagenomi, with a deadline of November 25, 2024, for investors to seek the role of lead plaintiff [1][4]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [1]. Group 2: Allegations Against Metagenomi - The complaint alleges that Metagenomi and its executives made false and misleading statements regarding their collaboration with Moderna, which was a key aspect of their business model [2]. - Metagenomi's initial public offering took place on February 13, 2024, selling 6.25 million shares at $15 per share [3]. - The collaboration with Moderna was terminated on May 1, 2024, leading to a significant drop in Metagenomi's stock price from $7.04 to $6.17 per share within a day [3]. Group 3: Investor Participation and Information - The lead plaintiff in the class action is defined as the investor with the largest financial interest who is typical of class members [4]. - Any member of the putative class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [4]. - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Metagenomi's conduct [4].

NEW YORK, Oct. 18, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of Metagenomi, Inc. (NASDAQ: MGX) pursuant and/or traceable to the Company's initial public offering conducted between February 9 and 13, 2024 (the "IPO"), of the important November 25, 2024 lead plaintiff deadline. SO WHAT: If you purchased Metagenomi stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. ...

PHILADELPHIA, Oct. 18, 2024 (GLOBE NEWSWIRE) -- A securities class action lawsuit has been filed against Metagenomi Inc. ("Metagenomi" or the "Company") (NASDAQ: MGX). The lawsuit has been filed on behalf of purchasers of Metagenomi securities between February 6, 2024 and September 26, 2024, inclusive (the "Class Period"). CLICK HERE TO LEARN MORE ABOUT THIS LAWSUIT. Investors who purchased or acquired METAGENOMI securities during the Class Period may, no later than NOVEMBER 25, 2024, seek to be appointed a ...